Park Insung, Yoshitake Rikako, Kioka Kazuki, Ishihara Asuka, Yajima Katsuhiko, Kawana Fusae, Kokubo Toshio, Matsuzaki Ichiyo, Kanbayashi Takashi, Yanagisawa Masashi, Tokuyama Kumpei
International Institute for Integrative Sleep Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.
Faculty of Health and Sports Sciences, University of Tsukuba, Tsukuba, Ibaraki 305-8574, Japan.
iScience. 2024 Jun 6;27(7):110212. doi: 10.1016/j.isci.2024.110212. eCollection 2024 Jul 19.
Suvorexant is an orexin receptor antagonist that targets the wake-promoting system. Orexin is also known to regulate energy metabolism in rodents, but its role in humans remains largely unknown. Here, we assessed the effect of suvorexant (20 mg) on energy metabolism during sleep and shortly after awakening in a randomized, double-blind, placebo-controlled, crossover study in 14 healthy men. Suvorexant increased rapid eye movement (REM) but decreased nonrapid eye movement (NREM) stage 1. Energy expenditure during wake after sleep onset (WASO) was higher than that during NREM and REM sleep in the placebo but not in the suvorexant trial, suggesting that the increase in energy expenditure during WASO was due to an activation of the orexin system. Fat oxidation during sleep increased, and its effect remained after waking the next morning. Suvorexant decreased protein catabolism but did not affect overall energy expenditure. The orexin system may affect fat oxidation independent of its roles in sleep regulation in humans.
苏沃雷生是一种针对促醒系统的食欲素受体拮抗剂。已知食欲素在啮齿动物中调节能量代谢，但其在人类中的作用仍大多未知。在此，我们在一项针对14名健康男性的随机、双盲、安慰剂对照、交叉研究中，评估了苏沃雷生（20毫克）对睡眠期间及醒来后不久能量代谢的影响。苏沃雷生增加了快速眼动（REM）睡眠，但减少了非快速眼动（NREM）睡眠的第1阶段。在安慰剂组中，睡眠开始后觉醒期间（WASO）的能量消耗高于NREM和REM睡眠期间，但在苏沃雷生试验中并非如此，这表明WASO期间能量消耗的增加是由于食欲素系统的激活。睡眠期间脂肪氧化增加，且其影响在第二天早晨醒来后仍然存在。苏沃雷生减少了蛋白质分解代谢，但不影响总体能量消耗。食欲素系统可能独立于其在人类睡眠调节中的作用影响脂肪氧化。
